High-Risk Breast Cancer


  • Joseph Ragaz
  • Irving M. Ariel

Table of contents

  1. Front Matter
    Pages I-XI
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. J. Ragaz, I. M. Ariel
      Pages 3-23
  3. Epidemiology

    1. Front Matter
      Pages 25-25
    2. P. R. Band, A. J. Coldman, M. Deschamps
      Pages 27-41
  4. Oncogenes

    1. Front Matter
      Pages 43-43
    2. J. MacKay, M. Steel
      Pages 45-68
    3. J. Fiore, M. V. Viola
      Pages 69-81
  5. Flow Cytometry

    1. Front Matter
      Pages 83-83
    2. H. B. Muss, T. E. Kute
      Pages 103-119
    3. J. Le Riche, J. Atiba, J. Ragaz, G. De Jong
      Pages 120-137
  6. Tumor Kinetics

    1. Front Matter
      Pages 139-139
    2. L. Simpson-Herren
      Pages 172-193
  7. Receptor

    1. Front Matter
      Pages 195-195
    2. D. E. Merkel, S. M. Hill, W. L. McGuire
      Pages 197-212
  8. Pathology

  9. Mammography

  10. Immunology

  11. General

  12. Back Matter
    Pages 379-383

About this book


The most meaningful reward to clinicians and researchers is the absence of recurrent malignancy in their patients. While in some patients the disease will be cured by resection alone, in other similarly staged cases the disease will recur despite adequate loco regional and systemic therapies. Hence, risk assessment is a complex issue with many related or unrelated prognostic factors determining outcome. The purpose of this volume is to review some of the most relevant prognostic factors of newly diagnosed breast cancer, focusing on fea­ tures determining the magnitude of risk. The ultimate value of establishing the significance of each prognostic factor in a given patient will be the resulting ability to plan individu­ alized therapies for patients at different risk of recurrence at the time of diagnosis. To secure the maximum benefit for high-risk patients, while avoiding undue toxicity in those with low-risk lesions, a well-integrated analysis of all known prognostic factors will be essential in the early postdiagnos­ tic period. In addition to well-established staging criteria such as axillary nodes, tumor size, receptors, scanning and radiographic examinations, the more sophisticated labora­ tory techniques, as discussed by several authors herein, will playa crucial role in risk assessment. Most of them, - ploidy determination, oncogenes, tumor markers, monoclonal anti­ bodies, growth factors, etc. -are presently available in only a minority of treatment centers.


breast cancer cancer cancer treatment diagnosis hormones mammography pathology

Editors and affiliations

  • Joseph Ragaz
    • 1
  • Irving M. Ariel
    • 2
  1. 1.Medical OncologyCancer Control Agency of British ColumbiaVancouverCanada
  2. 2.Foundation for Clinical Research Inc.New YorkUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1989
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-73720-6
  • Online ISBN 978-3-642-73718-3
  • Buy this book on publisher's site